Micromet Inc.
Micromet, Inc. is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of the Company's antibodies are in
trials, while the remainder of its product pipeline is in preclinical development. The Company's product candidates in clinical and preclinical development are MT103 for Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma; MT110 for Adenocarcinoma; MT111 and EphA2 BiTE antibody for selected cancers; MCSP BiTE antibody for melanoma; Adecatumumab (MT201) for metastatic breast cancer and other adenocarcinoma; MT293 for solid tumors; MT228 for melanoma, and MT203 and MT204 for inflammatory diseases.
..